Morningstar

iShares U.S. Pharmaceuticals ETF IHE

Morningstar Medalist Rating
Medalist Rating as of | See iShares Investment Hub

Morningstar’s Analysis IHE

Will IHE outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable IHE’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the IHE management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of IHE’s parent organization’s priorities and whether they’re in line with investors’ interests.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

iShares US Pharmaceuticals ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

by Morningstar Automated Analysis
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings IHE

More IHE Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 79.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

24.39 373M
Healthcare

Johnson & Johnson

22.33 342M
Healthcare

Pfizer Inc

4.65 71M
Healthcare

Viatris Inc

4.54 69M
Healthcare

Zoetis Inc Class A

4.50 69M
Healthcare

Merck & Co Inc

4.47 68M
Healthcare

Royalty Pharma PLC Class A

4.32 66M
Healthcare

Bristol-Myers Squibb Co

4.28 65M
Healthcare

Jazz Pharmaceuticals PLC

3.39 52M
Healthcare

Corcept Therapeutics Inc

2.57 39M
Healthcare

Sponsor Center